Metabonomic analysis of cerebrospinal fluid in epilepsy
2022 Annals of Translational Medicine. All rights reserved..
Background: We sought to explore the relationship between epilepsy and cerebrospinal fluid metabolomics and identify biomarkers for the diagnosis, treatment, and prognosis of epilepsy.
Methods: In total, 23 epileptic patients treated at The First Affiliated Hospital of Dalian Medical University from April 2019 to September 2019 were selected for the disease group and 13 non-epileptic patients were selected for the control group. Cerebrospinal fluid samples were collected from both groups, and the metabolites were analyzed by gas chromatography-mass spectrometry. The metabolites differentially expressed in the cerebrospinal fluid samples were identified. A differential metabolite enrichment analysis was performed to determine the metabolic pathways.
Results: Using a variable importance in the projection value >1 and a P value <0.05 as the screening criteria, we found that 3 metabolites (i.e., alpha-ketoisocaproic acid 1, xylose 1, and glycine 2) were differentially expressed in the cerebrospinal fluid of the 23 epileptic patients compared to the 13 non-epileptic patients. Alpha-ketoisocaproic acid 1 and xylose 1 were highly expressed in the epileptic cerebrospinal fluid samples, while glycine 2 was lowly expressed in the epileptic cerebrospinal fluid samples. Additionally, the 3 metabolites were significantly enriched in the 5 metabolic pathways of primary bile acid biosynthesis, valine, leucine, and isoleucine degradation, glutathione metabolism, glyoxylate and dicarboxylate metabolism, and glycine, serine, and threonine metabolism.
Conclusions: The present study examined the metabolites of the cerebrospinal fluid of epileptic patients and non-epileptic patients. Our findings provide insights that may inform the discovery of therapeutic targets and diagnostic markers for epilepsy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Annals of translational medicine - 10(2022), 8 vom: 10. Apr., Seite 449 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Niu, Di [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 30.08.2022 published: Print Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.21037/atm-22-1219 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM340943076 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM340943076 | ||
| 003 | DE-627 | ||
| 005 | 20231226010628.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21037/atm-22-1219 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1136.xml |
| 035 | |a (DE-627)NLM340943076 | ||
| 035 | |a (NLM)35571432 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Niu, Di |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Metabonomic analysis of cerebrospinal fluid in epilepsy |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 30.08.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a 2022 Annals of Translational Medicine. All rights reserved. | ||
| 520 | |a Background: We sought to explore the relationship between epilepsy and cerebrospinal fluid metabolomics and identify biomarkers for the diagnosis, treatment, and prognosis of epilepsy | ||
| 520 | |a Methods: In total, 23 epileptic patients treated at The First Affiliated Hospital of Dalian Medical University from April 2019 to September 2019 were selected for the disease group and 13 non-epileptic patients were selected for the control group. Cerebrospinal fluid samples were collected from both groups, and the metabolites were analyzed by gas chromatography-mass spectrometry. The metabolites differentially expressed in the cerebrospinal fluid samples were identified. A differential metabolite enrichment analysis was performed to determine the metabolic pathways | ||
| 520 | |a Results: Using a variable importance in the projection value >1 and a P value <0.05 as the screening criteria, we found that 3 metabolites (i.e., alpha-ketoisocaproic acid 1, xylose 1, and glycine 2) were differentially expressed in the cerebrospinal fluid of the 23 epileptic patients compared to the 13 non-epileptic patients. Alpha-ketoisocaproic acid 1 and xylose 1 were highly expressed in the epileptic cerebrospinal fluid samples, while glycine 2 was lowly expressed in the epileptic cerebrospinal fluid samples. Additionally, the 3 metabolites were significantly enriched in the 5 metabolic pathways of primary bile acid biosynthesis, valine, leucine, and isoleucine degradation, glutathione metabolism, glyoxylate and dicarboxylate metabolism, and glycine, serine, and threonine metabolism | ||
| 520 | |a Conclusions: The present study examined the metabolites of the cerebrospinal fluid of epileptic patients and non-epileptic patients. Our findings provide insights that may inform the discovery of therapeutic targets and diagnostic markers for epilepsy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Epilepsy | |
| 650 | 4 | |a cerebrospinal fluid | |
| 650 | 4 | |a metabolites | |
| 700 | 1 | |a Sun, Pin |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Fenghua |e verfasserin |4 aut | |
| 700 | 1 | |a Song, Fan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of translational medicine |d 2013 |g 10(2022), 8 vom: 10. Apr., Seite 449 |w (DE-627)NLM23455374X |x 2305-5839 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2022 |g number:8 |g day:10 |g month:04 |g pages:449 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21037/atm-22-1219 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2022 |e 8 |b 10 |c 04 |h 449 | ||